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G6PC3 deficiency typically causes severe congenital neutropenia, associated with sus-
ceptibility to infections, cardiac and urogenital abnormalities. However, here we describe 
two boys of Pakistani origin who were found to have G6PC3 deficiency due to c.130 C>T 
mutation, but who have clinical phenotypes that are typical for a systemic autoinflammatory 
syndrome. The index case presented with combination of unexplained fevers, severe muco-
sal ulcers, abdominal symptoms, and inflammatory arthritis. He eventually fully responded 
to anti-TNF therapy. In this study, we show that compared with healthy controls, neutrophils 
and monocytes from patients have reduced glycolytic reserve. Considering that healthy 
myeloid cells have been shown to switch their metabolic pathways to glycolysis in response 
to inflammatory cues, we studied what impact this might have on production of the inflam-
matory cytokines. We have demonstrated that patients’ monocytes, in response to lipo-
polysaccharide, show significantly increased production of IL-1β and IL-18, which is NLRP3 
inflammasome dependent. Furthermore, additional whole blood assays have also shown an 
enhanced production of IL-6 and TNF from the patients’ cells. These cases provide further 
proof that autoinflammatory complications are also seen within the spectrum of primary 
immune deficiencies, and resulting from a wider dysregulation of the immune responses.
Keywords: G6PC3, systemic autoinflammatory syndromes, pID, neutropenia, adalimumab
BaCKGRoUND
Systemic autoinflammatory disorders (SAIDs) can manifest as periodic sterile fevers, with or without 
tissue specific signs and symptoms such as skin rashes, serositis, synovitis, and mucosal ulceration. In 
well-defined monogenic SAIDs, the pathogenic mutation typically leads to gain-of-function within 
the innate-immune-mediated inflammatory pathways (1). However, it is increasingly recognized 
Abbreviations: ASC, apoptosis associated speck-like protein containing a CARD; CRP, C-reactive protein; G6PC3, 
glucose-6-phosphatase catalytic subunit 3; IBD, inflammatory bowel disease; IL, interleukin; LPS, lipopolysaccharide; MEFV, 
Mediterranean fever; ROS, reactive oxygen species; MVK, mevalonate kinase; NLRP3, NACHT, LRR, and PYD domains-
containing protein 3; PMA, phorbol myristate acetate; SAA, serum amyloid A; SAID, systemic autoinflammatory disorder; 
TNFRSF1A, tumor necrosis factor receptor superfamily member 1A.
FIGURe 1 | Clinical characteristics of patients with G6PC3 c.130 C>T homozygous mutation. (a) Family pedigree, (B) longitudinal neutrophil count measurements, 
(C) neutrophil oxidative burst. Local reference ranges are shown in the bars. >98% of neutrophils and monocytes showed appropriate shift following 
lipopolysaccharide (LPS) and phorbol myristate acetate (PMA) stimulation. (D) Histology slide from bone marrow biopsy showing normal neutrophil maturation.
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that autoinflammatory complications are also seen within the 
spectrum of primary immune deficiencies (2). Here, we describe 
the case of two brothers who presented with SAID but were found 
to have a mutation in G6PC3. This mutation typically causes car-
diac and urogenital abnormalities (3–6), and severe congenital 
neutropenia associated with susceptibility to infections, but not 
usually SAID.
Case pReseNtatIoN
The index patient is a 12-year-old male, who was born healthy 
at term to consanguineous parents of Pakistani origin. At 1 year 
of age, he developed mild, self-limiting oral aphthous ulcers. 
Neutropenia was first noted on an incidental blood test when he 
was 3 years old. From the age of 7 years, he suffered progressive, 
deep oral ulceration severe enough to result in complete dyspha-
gia and several hospital admissions. He also developed transient 
perianal ulceration associated with episodic diarrhea and 
intermittent abdominal pain. Other pertinent features included 
a swinging pyrexia (39°C), oligoarthritis (knees) associated with 
a joint effusion on at least one occasion, and cervical lymphad-
enopathy. At the age of 11, he developed a rash on his right shin. 
The rash was diagnosed as erythema nodosum. He had no eye 
symptoms, or any other organ involvement. The only notable 
infections were paronychial nail infections and a conjunctival 
infection due to herpes simplex virus. The patient had two other 
siblings, and only the younger brother who initially was asymp-
tomatic, later developed similar but less severe clinical features. 
There was no other significant family history of inflammatory 
disorders. The index patient responded well to prednisolone, but 
he remained dependent on high doses of the steroid. The trial of 
colchicine was ineffective, but he subsequently responded fully 
to adalimumab.
CLINICaL aND LaBoRatoRY 
INVestIGatIoNs
Routine investigations revealed a cyclical neutropenia (Figure 1B) 
and negative autoimmune screen, which included antinuclear 
and antineutrophil cytoplasmic antibodies. Septic screen was 
also negative and included chest X-ray, blood cultures, and PCR 
for Epstein–Barr virus, cytomegalovirus, and adenovirus. During 
flares, he was found to have increased acute phase response with 
highly elevated C-reactive protein (300  mg/L), elevated serum 
amyloid A (45.2  mg/L), normocytic anemia, and polyclonal 
increase in IgG and IgM. Extensive investigations of the gastro-
intestinal tract included fecal calprotectin, which was raised at 
600  µg/g (normally <50 μg/g), normal abdominal ultrasound, 
FIGURe 2 | Whole blood lipopolysaccharide (LPS) stimulation and cytokine responses. Whole blood was diluted 1:5 with Roswell Park Memorial Institute medium 
into 96-well F plates (Corning) and activated by single stimulation or co-stimulations as indicated with LPS (1 µg/mL; List Biochemicals), + others. Supernatants 
were taken at 24 h. Cytokines were measured with multiplexed particle based flow cytometry (a) TNFa (B) IL6 (C) IL-1β; (All measured with R+D Systems 
Fluorokinemap) on a Luminex analyzer (Bio-Plex, Bio-Rad, UK). Two-way ANOVA statistical test was used (p < 0.05).
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endoscopy, and colonoscopy with biopsies taken from the mouth 
ulcers, esophagus, antrum, duodenum, ileum, and throughout 
the large colon. Endoscopy showed generalized inflammation 
from distal esophagus to duodenum, while colonoscopy revealed 
localized areas of edema and ulceration in terminal ileum. The 
biopsies of the mouth ulcers showed marked diffuse chronic 
inflammation with an infiltrate of lymphocytes and plasma cells 
as well as focal superficial acute inflammation with ulceration 
of the mucosa and acute purulent exudate. There were no well-
formed discrete granulomas seen. Biopsies from the esophagus, 
antrum, duodenum, and ileum were all within normal limits. The 
colonic biopsies showed an equivocal mild increase in chronic 
inflammatory cells in the lamina propria. There was no evidence 
of active inflammation, glandular/architectural distortion, or 
granulomata. These changes were thought to be mild and of ques-
tionable significance. In summary, there was no definite evidence 
on these biopsies to support a formal diagnosis of inflammatory 
bowel disease (IBD). A bone marrow biopsy showed no obvious 
defects in neutrophil production or maturation (Figure  1D). 
Plain X-rays of the hips, knees, and pelvis taken during one of 
the flare episodes were all normal. An ultrasound scan of the hips 
and knees, which was done at the same time, did not show any 
effusion or synovial thickening. Subsequent to these investiga-
tions the patient did develop a clinically evident left knee effusion. 
Analysis of the synovial fluid during this episode showed heavy 
presence of polymorphs and mononuclear cells, with no visible 
crystals. Gram stains were negative, and subsequent synovial 
fluid culture was sterile.
Diagnoses of SAID and Behcet’s disease (BD) were consid-
ered. The genetic tests limited to analysis of MEFV, MVK, and 
TNFRSF1A genes were negative, but he was found to be HLA-B51 
positive. However, since several clinical features were not typical 
of BD the family was consented for whole-exome sequencing. 
Both brothers were found to have a homozygous mutation in 
G6PC3 c.130 C>T, p.(Pro44Ser) (Figure 1A).
Further immunological assessment showed that brothers had 
a normal neutrophil oxidative burst in response to lipopoly-
saccharide (LPS) and phorbol myristate acetate stimulation 
(Figure  1C). Since their clinical phenotypes were in keeping 
with SAID, we tested their ability to produce pro-inflammatory 
cytokines in vitro. The assays performed using the whole blood 
confirmed that the patients’ cells produced significantly higher 
levels of IL-1β and IL-6 compared with healthy control (HC) fol-
lowing 24-h stimulation with LPS (Figures 2B,C). The younger 
brother also showed increased TNF production (Figure  2A); 
at the time of testing, the older sibling was receiving anti-TNF 
therapy (adalimumab). The addition of IL-10 to the whole blood 
assay attenuated increased production of IL-1β, IL-6, and TNF, 
however, in the case of IL-1β, this was reduced in both brothers 
compared with HC (Figure 2).
FIGURe 3 | Levels of glycolysis and oxidative phosphorylation within monocytes and neutrophils from patients and healthy controls under basal and stressed 
conditions, with and without lipopolysaccharide (LPS) stimulation. Neutrophils were separated from the erythrocyte/granulocyte layer using ammonium chloride red 
cell lysis buffer (Sigma) after separating PBMC from the whole blood using the lymphoprep technique. Monocytes were separated further using magnetic beads 
(Miltenyi Biotec) for monocyte negative selection. Granulocytes and monocytes were seeded into the Agilent 96-well flux plate at 5 × 105 cells/well in triplicate wells 
and stimulated with or without LPS (10 ng/mL) (Invivogen) for 4 h. The XFp Cell Energy Phenotype Test (Agilent) was performed using the Agilent Xfe Seahorse 
Extracellular Flux Analyzer. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured by the Agilent Seahorse Metabolic Profiler 
using the Basal Metabolic Phenotype Assay as an indirect measurement of glycolysis and oxidative phosphorylation (OXPHOS) within live cell cultures. The baseline 
levels (gray) represent glycolysis (a) or OXPHOS (B) within the cells before metabolic stressors. The stressed levels (superimposed bars in white) represent glycolysis 
or OXPHOS post-oligomycin and FCCP injection. The two-way ANOVA statistical test was used (p < 0.05) and refers to the stressed (white) conditions.
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We then tested the ability of patients’ neutrophils and mono-
cytes to metabolically respond to LPS, specifically to induce 
glycolysis under conditions of metabolic stress. Healthy myeloid 
cells have been shown to switch their metabolic pathways to gly-
colysis in response to inflammatory cues such as LPS (7, 8). Given 
the important role of G6PC3 in gluconeogenesis and glycolysis, 
we hypothesized that this metabolic reprogramming might be 
impaired, predisposing enhanced production of pro-inflammatory 
cytokines. We found that at baseline, G6PC3 monocytes and 
neutrophils had comparable levels of glycolysis, measured by extra-
cellular acidification rate (Figure  3A). Following stimulation 
with LPS, both neutrophils and monocytes induced glycolysis as 
expected; however, this metabolic reprogramming was signifi-
cantly reduced in G6PC3 cells, indicating insufficient utilization 
of glycolysis in response to LPS. However, no obvious change in 
mitochondrial oxidative phosphorylation (OXPHOS), measured 
by oxygen consumption rate, was observed (Figure 3B) with the 
addition of LPS in monocytes from either HC or G6PC3 cells, 
although G6PC3 neutrophils had significantly reduced OXPHOS 
at baseline. We wondered if the metabolic changes we observed 
in granulocytes and monocytes had a more specific effect on 
NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) 
inflammasome complex, which is responsible for processing of 
pro-IL-1β and pro-IL-18 into their active components and is 
frequently dysregulated in many monogenic SAIDs. We found 
that the production of IL-1β and IL-18 from patients’ monocytes 
was significantly increased, compared with HC, after stimula-
tion of NLRP3 by priming and activation with LPS and ATP, 
respectively (Figures 4A,B). This was associated with increased 
release of apoptosis associated speck-like protein containing a 
CARD (ASC) specks (Figure  4C), which are typically released 
after stimulation of the NLRP3 inflammasome as the activated 
cells die by pyroproptosis.
DIsCUssIoN
Although G6PC3 deficiency is typically associated with predis-
position to recurrent severe infections and congenital/organ 
FIGURe 4 | IL-1β, IL-18 levels, and apoptosis associated speck-like protein containing a CARD (ASC) particle numbers following stimulation of monocytes with 
lipopolysaccharide (LPS)/ATP. Patients’ and healthy control (HC) monocytes were seeded at 1 × 106 cells/mL and stimulated with LPS (10 ng/mL) (Invivogen) for 4 h 
and then ATP (1 mM) (Invivogen) for 30 min. Supernatants were collected and used for IL-1β and IL-18 ELISA (ThermoFisher). The ASC particles were measured 
using directly conjugated anti-ASC ab (Cambridge Bioscience) and particles visualized by flow cytometry (BD LSRII). Two-way ANOVA statistical test was used 
(p < 0.05).
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abnormalities, inflammatory complications have also been 
described. For example, IBD resembling Crohn’s disease (CD) 
was noted in 3/14 patients in one case series (5), and in another 
report such complications were identified in 5/57 patients, with 
two patients being a sibling pair (6). Taken altogether, these 
reports suggest that the incidence of IBD in patients with G6PC3 
deficiency is higher compared with the general population (6). 
Furthermore, the clinical course of IBD in some of these cases 
seems to be severe, with two patients reported to have developed 
bowel stenosis requiring a partial colectomy (5) and another 
patient needing anti-TNF therapy following similar IBD-related 
complication (9). In at least one case, IBD was associated with a 
non-destructive polyarthritis, which was treated with corticoster-
oids (5). IBD as a complication of neutrophil-centered PID is not 
unique to G6PC3 deficiency, as it is also seen in other primary 
neutropenias (10–12) and in chronic granulomatous disease 
(CGD) (13). This association between inadequate neutrophil 
numbers or function and IBD is not entirely surprising, given 
that failure to adequately control gut microflora leading to dys-
regulated inflammatory responses in the gut, has also been linked 
with the pathogenesis of CD itself (14, 15).
In regard to the specific G6PC3 mutation we describe here, 
there are three additional patients with the same c.130 C>T 
homozygous variant reported in the literature (6). They were also 
of Pakistani origin, with no congenital/organ abnormalities, and 
one patient presented with mouth ulcers and transient myositis. 
Although patients with c.130 C>T genotype appear to have a 
milder phenotype, this is not necessarily associated with pres-
ervation of protein function. In vitro experiments show that this 
mutation causes almost total loss of phosphohydrolase activity 
of the G6Pase-β mutant (16). Interestingly, this does not appear 
to significantly affect neutrophil oxidative burst activity, which is 
in keeping with the clinical phenotype of our patients who did 
not suffer from serious infections. The lack of glycolytic respon-
siveness to LPS may affect other neutrophils responses. We have 
shown increased production of inflammatory cytokines from 
whole blood and reduced glycolysis of patient’s neutrophils and 
monocytes in response to LPS. The latter was evident once the 
cells were put under metabolic stress due to LPS stimulation and 
a cocktail of oligomycin and carbonyl cyanide 4-(trifluorometh-
oxy)phenylhydrazone (FCCP), and was associated with increased 
production of mature IL-1β, IL-18, and release of ASC specs. The 
6Mistry et al. G6PC3 Deficiency Associated With Autoinflammatory Complications
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impaired glycolytic function might result in insufficient ATP 
production and a resultant energy deprivation. Others have 
described this hypoglycolytic phenomenon in other immunologi-
cal diseases such as rheumatoid arthritis (RA), with deficiencies 
in the glycolytic enzyme phosphofructokinase (PFKFB3) (17). 
PFKFB3 deficiency and impaired glycolysis caused glucose to 
enter the pentose phosphate pathway in RA T cells. PFKFB3 defi-
ciency induced energy deprivation, increased NADPH, increased 
ROS consumption, impaired autophagy, and increased apoptosis. 
Our data suggest that hypoglycolytic monocytes and neutrophils 
are pro-inflammatory and have increased pyroptosis, a form of 
inflammatory cell death associated with ASC spec release into 
the extracellular space. Increased neutrophil cell death is known 
to occur in G6PC3 deficiency (18). Consequently, an energy 
deprived, hypoglycolytic cell might result in alterations in redox 
balance and reactive oxygen species consumption, known to 
activate the NLRP3 inflammasome (19).
It is important to appreciate the range of autoinflammatory 
complications associated with PIDs, since different treatment 
options might need to be considered. In the case of CGD, this 
concept has evolved significantly (20) and biological therapies 
targeting inflammatory cytokines, both TNF and IL-1 have 
now been used successfully to treat IBD and other associated 
autoinflammatory complications (21, 22). Similarly in this case, 
anti-TNF therapy has proven to be safe and effective treatment. 
However, using such therapies in PID cases does carry extra risk 
and requires increased vigilance for signs of emerging infective 
complications (23).
CoNCLUDING ReMaRKs
In summary, we show that a rare G6PC3 genotype can present 
with unique and varied clinical features in keeping with SAID. 
Furthermore, we show that hypoglycolytic responses and 
dysregulated production of pro-inflammatory cytokines might 
be central to this phenotype. Finally, we report that anti-TNF 
therapy is a safe and effective treatment for some of these patients.
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